Tolero Pharmaceuticals

About:

Tolero Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics to treat cancer and other life-threatening diseases.

Website: http://toleropharmaceuticals.com

Twitter/X: toleropharma

Top Investors: Alger

Description:

Tolero Pharmaceuticals is a biopharmaceutical company that discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering from chronic inflammatory diseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 which targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has a strategic partnership with MannKind Corporation. The company was founded in 2011 and is based in Salt Lake City, Utah.

Total Funding Amount:

$25.9M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Salt Lake City, Utah, United States

Founded Date:

2011-01-01

Founders:

Dallin M. Anderson, David J. Bearss

Number of Employees:

11-50

Last Funding Date:

2014-11-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai